Dozen Novel Agents Dream Of August US FDA Approval
Executive Summary
A stacked user fee goal lineup sets the stage for market showdowns in primary biliary cholangitis and IgA nephropathy, the first psychedelic approval decision, and lots of targeted cancer therapies.